Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018http://www.reportlinker.com/p0739439/Sickle-Cell-Anemia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary Scope- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sickle Cell Anemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Sickle Cell Anemia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Sickle Cell Anemia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Sickle Cell Anemia Therapeutics market
Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Sickle Cell Anemia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sickle Cell Anemia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Sickle Cell Anemia Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Sickle Cell Anemia Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 9
2.3 Etiology 9
2.4 Symptoms 10
2.5 Risk Factors 10
2.6 Diagnosis 11
2.7 Treatment and Management Pattern 12
2.8 GlobalData Pipeline Report Guidance 13
3 Sickle Cell Anemia Therapeutics - Market Characterization 14
3.1 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Global 14
3.2 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Global 16
3.3 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - the US 18
3.4 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - the US 19
3.5 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - the UK 20
3.6 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - the UK 21
3.7 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - France 22
3.8 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - France 23
3.9 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Germany 24
3.10 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Germany 25
3.11 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Italy 26
3.12 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Italy 27
3.13 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Spain 28
3.14 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Spain 29
3.15 Sickle Cell Anemia Therapeutics Market Size (2005-2010) and Forecast (20102018) - Japan 30
3.16 Drivers and Barriers for Sickle Cell Anemia 31
3.16.1 Drivers for the Sickle Cell Anemia Therapeutics Market 31
3.16.2 Barriers for the Sickle Cell Anemia Therapeutics Market 31
3.17 Opportunity and Unmet Needs 33
3.18 Key Takeaway 33
4 Sickle Cell Anemia Therapeutics Market - Competitive Assessment 34
4.1 Overview 34
4.1.1 Strategic Competitor Assessment 34
4.2 Product Profiles for the Major Products in Sickle Cell Anemia 35
4.2.1 Hydroxyurea 35
4.2.2 Penicillin V 36
4.3 Key Takeaway 36
5 Sickle Cell Anemia Therapeutics - Pipeline Assessment 37
5.1 Overview 37
5.2 Strategic Pipeline Assessment 37
5.3 Pipeline Analysis by Phase of Development 38
5.3.1 Sickle Cell Anemia Therapeutics - Phase II / III Pipeline 38
5.3.2 Sickle Cell Anemia Therapeutics - Phase II Pipeline 38
5.3.3 Sickle Cell Anemia Therapeutics - Phase I/II Pipeline 39
5.3.4 Sickle Cell Anemia Therapeutics - Phase I Pipeline 39
5.3.5 Sickle Cell Anemia Therapeutics - Preclinical Pipeline 39
5.3.6 Sickle Cell Anemia Therapeutics - Discovery Pipeline 39
5.4 Sickle Cell Anemia Therapeutics: Pipeline by Mechanism of Action 40
5.5 Sickle Cell Anemia Therapeutics - Other Promising Mechanisms of Action 41
5.6 Technology Trends Analytic Framework 41
5.7 Molecule Profile for Drugs under Phase II Clinical Development 43
5.7.1 Varespladib sodium (A-001) 43
5.7.2 Exjade (deferasirox, ICL670) 44
5.7.3 GMI-1070 45
5.7.4 HQK-1001 45
5.8 Key Takeaway 46
6 Sickle Cell Anemia Therapeutics - Clinical Trials Mapping 47
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 47
6.2 Clinical Trials by Phase 48
6.3 Clinical Trials by Trial Status 49
6.4 Prominent Sponsors 50
6.5 Top Sponsors Participating in Sickle Cell Anemia Therapeutics Clinical Trials 52
7 Sickle Cell Anemia Therapeutics - Strategic Assessment 53
7.1 Future Market Competition Scenario 53
8 Sickle Cell Anemia Therapeutics - Future Players 54
8.1 Introduction 54
8.2 Company Profiles for the Promising and Marketed Drugs 55
8.2.1 Anthera Pharmaceuticals Inc. (Anthera) 55
8.2.2 Novartis Pharmaceuticals 56
8.2.3 GlycoMimetics, Inc. 58
8.2.4 Pfizer 59
8.2.5 HemaQuest Pharmaceuticals Inc. 61
8.3 Other Companies in the Sickle Cell Anemia Market, 2011 62
9 Sickle Cell Anemia Therapeutics - Licensing and Partnership Deals 63
10 Sickle Cell Anemia Therapeutics - Appendix 65
10.1 Market Definitions 65
10.2 Abbreviations 65
10.3 Methodology 66
10.3.1 Coverage 66
10.3.2 Secondary Research 66
10.3.3 Forecasting 67
10.3.4 Primary Research 70
10.3.5 Expert Panel Validation 70
10.4 Contact Us 70
10.5 Disclaimer 70
10.6 Bibliography 71
List of Tables
Table 1: Prevalence of Sickle Cell Anemia in Major Markets in 2011 9
Table 2: Sickle Cell Anemia Therapeutics Market, Global, Revenue ($m), 2005-2010 14
Table 3: Sickle Cell Anemia Therapeutics Market, Global, Market Forecast ($m), 2010-2018 16
Table 4: Sickle Cell Anemia Therapeutics Market, the US, Revenue($m), 2005-2010 18
Table 5: Sickle Cell Anemia Therapeutics Market, the US, Market Forecast ($m), 2010-2018 19
Table 6: Sickle Cell Anemia Therapeutics Market, the UK, Revenue ($m), 2005-2010 20
Table 7: Sickle Cell Anemia Therapeutics Market, the UK, Market Forecast ($m), 2010-2018 21
Table 8: Sickle Cell Anemia Therapeutics Market, France, Revenue ($m), 2005-2010 22
Table 9: Sickle Cell Anemia Therapeutics Market, France, Market Forecast ($m), 2010-2018 23
Table 10: Sickle Cell Anemia Therapeutics Market, Germany, Revenue ($m), 2005-2010 24
Table 11: Sickle Cell Anemia Therapeutics Market, Germany, Market Forecast ($m),2010-2018 25
Table 12: Sickle Cell Anemia Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
Table 13: Sickle Cell Anemia Therapeutics Market, Italy, Market Forecast ($m), 2010-2018 27
Table 14: Sickle Cell Anemia Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Table 15: Sickle Cell Anemia Therapeutics Market, Spain, Market Forecast ($m), 2010-2018 29
Table 16: Efficacy results of hydroxyurea for adults with sickle cell anemia 35
Table 17: Safety results of hydroxyurea for adults with sickle cell anemia 35
Table 18: Sickle Cell Anemia Therapeutics - Phase II / III Pipeline, 2011 38
Table 19: Sickle Cell Anemia Therapeutics - Phase II Pipeline, 2011 38
Table 20: Sickle Cell Anemia Therapeutics - Phase I/II Pipeline, 2011 39
Table 21: Sickle Cell Anemia Therapeutics - Phase I Pipeline, 2011 39
Table 22: Sickle Cell Anemia Therapeutics - Preclinical Pipeline, 2011 39
Table 23: Sickle Cell Anemia Therapeutics - Discovery Pipeline, 2011 39
Table 24: Sickle Cell Anemia Therapeutics - Other Promising Mechanisms of Action 41
Table 25: Adverse Effects Due to Deferasirox 44
Table 26: Sickle Cell Anemia Therapeutics - Clinical Mapping by Region / Country, 2011 47
Table 27: Sickle Cell Anemia Therapeutics - Clinical Mapping by Phase, 2011 48
Table 28: Sickle Cell Anemia Therapeutics - Clinical Mapping by Trial Status, 2011 49
Table 29: Sickle Cell Anemia Therapeutics - Clinical Mapping by Overall Sponsors, 2011 50
Table 30: Sickle Cell Anemia Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 51
Table 31: Sickle Cell Anemia Therapeutics - Clinical Mapping by Top Sponsors, 2011 52
Table 32: Anthera Pharmaceuticals - Pipeline Products, 2011 55
Table 33: Anthera Pharmaceuticals - Sickle Cell Anemia Pipeline Product, 2011 55
Table 34: Novartis Pharmaceuticals - Pipeline Products, 2011 57
Table 35: Novartis Pharmaceuticals - Sickle Cell Anemia Pipeline Product, 2011 58
Table 36: Glyco Mimetics Inc.- Pipeline Products, 2011 58
Table 37: Glyco Mimetics Inc.- Sickle Cell Anemia Pipeline Product, 2011 58
Table 38: HemaQuest Pharmaceuticals Inc. - Pipeline Product, 2011 61
Table 39: HemaQuest Pharmaceuticals Inc. - Sickle Cell Anemia Pipeline Product, 2011 61
Table 40: Sickle Cell Anemia Therapeutics - Future Players, 2011 62
Table 41: Sickle Cell Anemia Therapeutics, Global, Deals 63
List of Figures
Figure 1: Pictorial Representation of Normal and Abnormal Red Blood Cells 7
Figure 2: Inheritance Pattern of Sickle Cell Trait 8
Figure 3: Types of Sickle Cell Disease 8
Figure 4: Symptoms of Sickle Cell Anemia 10
Figure 5: Complications of Sickle Cell Anemia 11
Figure 6: Sickle Cell Anemia Therapeutics Market, Global, Revenue ($m), 2005-2010 14
Figure 7: Sickle Cell Anemia Therapeutics , Market Share (%), 2010 15
Figure 8: Sickle Cell Anemia Therapeutics Market, Global, Market Forecast ($m), 2010-2018 16
Figure 9:Sickle Cell Anemia Therapeutics, Market Share (%), 2018 17
Figure 10: Sickle Cell Anemia Therapeutics Market, the US, Revenue ($m), 2005-2010 18
Figure 11: Sickle Cell Anemia Therapeutics Market, the US, Market Forecast ($m), 2010-2018 19
Figure 12: Sickle Cell Anemia Therapeutics Market, the UK, Revenue ($m), 2005-2010 20
Figure 13: Sickle Cell Anemia Therapeutics Market, the UK, Market Forecast ($m), 2010-2018 21
Figure 14: Sickle Cell Anemia Therapeutics Market, France, Revenue ($m), 2005-2010 22
Figure 15: Sickle Cell Anemia Therapeutics Market, France, Market Forecast ($m), 2010-2018 23
Figure 16: Sickle Cell Anemia Therapeutics Market, Germany, Revenue ($m), 2005-2010 24
Figure 17: Sickle Cell Anemia Therapeutics Market, Germany, Market Forecast ($m), 2010-2018 25
Figure 18: Sickle Cell Anemia Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
Figure 19: Sickle Cell Anemia Therapeutics Market, Italy, Market Forecast ($m), 2010-2018 27
Figure 20: Sickle Cell Anemia Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Figure 21: Sickle Cell Anemia Therapeutics Market, Spain, Market Forecast ($m), 2010-2018 29
Figure 22: Sickle Cell Anemia Therapeutics Market, Quotes from Japanese Hematologists 30
Figure 23: Sickle Cell Anemia Therapeutics - Drivers and Barriers, 2011 32
Figure 24: Opportunity and Unmet Need for adults in Sickle Cell Anemia Therapeutics Market, 2011 33
Figure 25: Strategic Competitor Assessment of Sickle Cell Anemia Therapeutics Market, 2011 34
Figure 26: Sickle Cell Anemia Therapeutics Pipeline by Phase of Clinical Development, 2011 38
Figure 27: Sickle Cell Anemia Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 40
Figure 28: Technology Trends Analytic Framework of the Sickle Cell Anemia Therapeutics Pipeline, 2011 42
Figure 29: Technology Trends Analytic Framework of the Sickle Cell Anemia Therapeutics Pipeline - Description, 2011 43
Figure 30: Sickle Cell Anemia Therapeutics - Clinical Mapping by Region / Country, 2011 47
Figure 31: Sickle Cell Anemia Therapeutics - Clinical Mapping by Phase, 2011 48
Figure 32: Sickle Cell Anemia Therapeutics - Clinical Mapping by Trial Status, 2011 49
Figure 33: Sickle Cell Anemia Therapeutics - Clinical Mapping by Overall Sponsors, 2011 50
Figure 34: Sickle Cell Anemia Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 51
Figure 35: Sickle Cell Anemia Therapeutics - Clinical Mapping by Top Sponsors, 2011 52
Figure 36: Sickle Cell Anemia Therapeutics - Implications for Future Market Competition, 2011 53
Figure 37: Sickle Cell Anemia Therapeutics - Clinical Pipeline by Company, 2011 54
Figure 38: GlobalData Market Forecasting Model 69
Companies mentioned
Anthera Pharmaceuticals Inc. (Anthera)
Novartis Pharmaceuticals
GlycoMimetics, Inc.
Pfizer
HemaQuest Pharmaceuticals Inc.
To order this report:Therapy Industry: Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018More
Market Research ReportCheck our
Industry Analysis and InsightsNicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article